MX2020003670A - Metodos para tratar infecciones bacterianas. - Google Patents

Metodos para tratar infecciones bacterianas.

Info

Publication number
MX2020003670A
MX2020003670A MX2020003670A MX2020003670A MX2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A
Authority
MX
Mexico
Prior art keywords
subject
methods
subjects
treating bacterial
transplant
Prior art date
Application number
MX2020003670A
Other languages
English (en)
Inventor
Michael N Dudley
Elizabeth Alexander
Jeff Loutit
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65994826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020003670(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of MX2020003670A publication Critical patent/MX2020003670A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para tratar la infección bacteriana en sujetos inmunodeprimidos y sujetos con una o mas neoplasias subyacentes que incluyen la administración al sujeto de una combinación de meropenem y vaborbactam. Los sujetos adecuados a tratar pueden incluir un sujeto con un antecedente de leucemia o linfoma en curso, un sujeto que ha tenido un trasplante de órgano, trasplante de células madre, trasplante de medula ósea, o esplenectomia, un sujeto que recibe medicamentos inmunosupresores, un sujeto que recibe quimioterapia ablativa de medula ósea, un sujeto con neutropenia y un sujeto que padece o que ha padecido de una neoplasia.
MX2020003670A 2017-10-03 2018-10-01 Metodos para tratar infecciones bacterianas. MX2020003670A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762567702P 2017-10-03 2017-10-03
US201862657402P 2018-04-13 2018-04-13
PCT/US2018/053772 WO2019070591A1 (en) 2017-10-03 2018-10-01 METHODS OF TREATING BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
MX2020003670A true MX2020003670A (es) 2020-08-03

Family

ID=65994826

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003670A MX2020003670A (es) 2017-10-03 2018-10-01 Metodos para tratar infecciones bacterianas.

Country Status (15)

Country Link
US (2) US11376237B2 (es)
EP (1) EP3691652A4 (es)
JP (1) JP2020536092A (es)
KR (1) KR20200066664A (es)
CN (1) CN111432821A (es)
AU (1) AU2018345317A1 (es)
BR (1) BR112020006658A2 (es)
CA (1) CA3078238A1 (es)
CL (1) CL2020000892A1 (es)
JO (1) JOP20200075A1 (es)
MX (1) MX2020003670A (es)
PH (1) PH12020550249A1 (es)
SG (1) SG11202003009QA (es)
TW (2) TW202400146A (es)
WO (1) WO2019070591A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111432821A (zh) 2017-10-03 2020-07-17 梅琳塔治疗公司 治疗细菌感染的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN112755039A (zh) * 2015-04-24 2021-05-07 莱姆派克斯制药公司 治疗细菌感染的方法
MX2019008281A (es) * 2017-01-09 2019-12-02 Rempex Pharmaceuticals Inc Metodos para tratar infecciones bacterianas.
CN111432821A (zh) 2017-10-03 2020-07-17 梅琳塔治疗公司 治疗细菌感染的方法

Also Published As

Publication number Publication date
CN111432821A (zh) 2020-07-17
TW201922241A (zh) 2019-06-16
US20220288024A1 (en) 2022-09-15
US11376237B2 (en) 2022-07-05
PH12020550249A1 (en) 2021-02-15
EP3691652A4 (en) 2021-07-07
SG11202003009QA (en) 2020-04-29
WO2019070591A1 (en) 2019-04-11
BR112020006658A2 (pt) 2020-09-24
US20200297695A1 (en) 2020-09-24
CL2020000892A1 (es) 2020-10-23
EP3691652A1 (en) 2020-08-12
CA3078238A1 (en) 2019-04-11
JOP20200075A1 (ar) 2020-04-30
AU2018345317A1 (en) 2020-05-07
KR20200066664A (ko) 2020-06-10
JP2020536092A (ja) 2020-12-10
TW202400146A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2020013169A (es) Conjugados de camptotecina.
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
MX2022001075A (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
BR112017028413A2 (pt) peptídeos antimicrobianos estabilizados
BR112018072560A2 (pt) terapia de combinação para tratamento do câncer
CL2022001752A1 (es) Compuesto de piridazinil-tiazolcarboxamida
MX2019007613A (es) Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos.
EA202191632A1 (ru) Ахромосомные динамические активные системы
ES2525137B1 (es) Agentes para tratar el mieloma múltiple
BR112017006113A2 (pt) combinações sinérgicas de auristatina
MX2021005603A (es) Aparato y métodos para dispositivos de vaporización con varios atomizadores, de varias cámaras.
MX2017009450A (es) Composicion yodofora novedosa y metodos de uso.
WO2018009528A8 (en) Combination cancer immunotherapies with arginine depletion agents
CO2018008449A2 (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
MX2020000249A (es) Composiciones antimicrobianas efectivas contra bacterias y hongos.
MX2021005956A (es) Composiciones biologicas secas y metodos de las mismas.
CL2018001911A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2021001044A1 (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria
MX2020003670A (es) Metodos para tratar infecciones bacterianas.
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer